Granted Patent
B2
US 12,740,954 · App. 19/400,211 · Granted Sep 22, 2026
Treatment for interstitial lung disease
Inventors:
Leigh Peterson (Hillsborough, NC); Peter Smith (Durham, NC); Chunqin Deng (Chapel Hill, NC)
Assignee:
United Therapeutics Corporation
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Methods of treating of interstitial lung disease, reducing pulmonary function decline in a subject with interstitial lung disease (ILD), and increasing forced vital capacity (FVC) in a subject suffering from ILD are provided, wherein the methods include administration of treprostinil.
Claims (24)
1 . A method of improving exercise capacity in a patient having pulmonary hypertension associated with interstitial lung disease, comprising administering by inhalation to the patient having pulmonary hypertension associated with interstitial lung disease an effective amount of at least 15 micrograms up to a maximum tolerated dose of treprostinil or a pharmaceutically acceptable salt thereof in a single administration event that comprises at least 6 micrograms per breath, wherein 4 single administration events are performed per day with a dry powder inhaler comprising a dry powder comprising treprostinil or a pharmaceutically acceptable salt thereof and (E)-3,6-bis[4-(N-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine.
2 . The method of claim 1 , wherein said administering provides a statistically significant increase of a 6 minutes walk distance in the patient after 8 weeks of the administering.
3 . The method of claim 1 , wherein said administering provides a statistically significant increase of a 6 minutes walk distance in the patient after 12 weeks of the administering.
4 . The method of claim 1 , wherein said administering provides a statistically significant increase of a 6 minutes walk distance in the patient after 16 weeks of the administering.
5 . The method of claim 1 , wherein said administering increases a 6 minutes walk distance of the patient by at least 10 m after 8 weeks of the administering.
6 . The method of claim 1 , wherein said administering increases a 6 minutes walk distance of the patient by at least 10 m after 12 weeks of the administering.
7 . The method of claim 1 , wherein said administering increases a 6 minutes walk distance of the patient by at least 10 m after 16 weeks of the administering.
8 . The method of claim 1 , wherein said administering reduces a plasma concentration of NT-proBNP in the patient by at least 200 pg/ml after 8 weeks of the administering.
9 . The method of claim 1 , wherein said administering reduces a plasma concentration of NT-proBNP in the patient by at least 200 pg/ml after 12 weeks of the administering.
10 . The method of claim 1 , wherein said administering reduces a plasma concentration of NT-proBNP in the patient by at least 200 pg/ml after 16 weeks of the administering.
11 . The method of claim 1 , wherein said administering provides a statistically significant reduction of at least one exacerbation of the interstitial lung disease.
12 . The method of claim 1 , wherein said administering provides a statistically significant reduction of clinical worsening events due to the interstitial lung disease.
13 . The method of claim 12 , wherein the clinical worsening events comprise at least one of hospitalization for cardiopulmonary indication and a decrease in a 6-minute walk distance by more than 15% compared to a baseline 6-minute walk distance prior to the administering.
14 . The method of claim 1 , wherein said administering provides a statistically significant improvement of forced vital capacity (FVC) in the patient after 8 weeks of the administering.
15 . The method of claim 1 , wherein said administering provides a statistically significant improvement of forced vital capacity (FVC) in the patient after 12 weeks of the administering.
16 . The method of claim 1 , wherein said administering provides a statistically significant improvement of forced vital capacity (FVC) in the patient after 16 weeks of the administering.
17 . The method of claim 14 , wherein said improvement is an improvement in the forced vital capacity (FVC) in the patient by at least 20 ml.
18 . The method of claim 15 , wherein said improvement is an improvement in the forced vital capacity (FVC) in the patient by at least 20 ml.
19 . The method of claim 16 , wherein said improvement is an improvement in the forced vital capacity (FVC) in the patient by at least 20 ml.
20 . The method of claim 1 , wherein the effective amount of treprostinil or a pharmaceutically acceptable salt administered to the patient in a single inhalation administration event is from 15 μg to 100 μg.
21 . The method of claim 20 , wherein the single inhalation administration event does not exceed 15 breaths by the patient.
22 . The method of claim 1 , wherein said administering increases a 6 minutes walk distance of the patient by at least 15 m after 8 weeks of the administering.
23 . The method of claim 1 , wherein said administering increases a 6 minutes walk distance of the patient by at least 15 m after 12 weeks of the administering.
24 . The method of claim 1 , wherein said administering increases a 6 minutes walk distance of the patient by at least 15 m after 16 weeks of the administering.
Continuity (6)
Continuation
18219944
· Jul 10, 2023
Provisional Application
63160611
· Mar 12, 2021
Provisional Application
63011810
· Apr 17, 2020
References Cited (400)
US 3664337A
· Lindsey et al.
· 1972
[cited by applicant]
US 4001650A
· Romain
· 1977
[cited by applicant]
US 4007238A
· Glenn
· 1977
[cited by applicant]
US 4281113A
· Axen et al.
· 1981
[cited by applicant]
US 4306075A
· Aristoff
· 1981
[cited by applicant]
US 4306076A
· Nelson
· 1981
[cited by applicant]
US 4349689A
· Aristoff
· 1982
[cited by applicant]
US 4473296A
· Shofner et al.
· 1984
[cited by applicant]
US 4486598A
· Aristoff
· 1984
[cited by applicant]
US 4495944A
· Brisson et al.
· 1985
[cited by applicant]
US 4635647A
· Choksi
· 1987
[cited by applicant]
US 4668814A
· Aristoff
· 1987
[cited by applicant]
US 4677975A
· Edgar et al.
· 1987
[cited by applicant]
US 4683330A
· Aristoff
· 1987
[cited by applicant]
US 4692464A
· Skuballa et al.
· 1987
[cited by applicant]
US 4708963A
· Skuballa et al.
· 1987
[cited by applicant]
US 4976259A
· Higson et al.
· 1990
[cited by applicant]
US 4984158A
· Hillsman
· 1991
[cited by applicant]
US 5063922A
· Hakkinen
· 1991
[cited by applicant]
US 5080093A
· Raabe et al.
· 1992
[cited by applicant]
US 5153222A
· Tadepalli et al.
· 1992
[cited by applicant]
US 5234953A
· Crow et al.
· 1993
[cited by applicant]
US 5322057A
· Raabe et al.
· 1994
[cited by applicant]
US 5361989A
· Merchat et al.
· 1994
[cited by applicant]
US 5363842A
· Mishelevich et al.
· 1994
[cited by applicant]
US 5497763A
· Lloyd et al.
· 1996
[cited by applicant]
US 5551416A
· Stimpson et al.
· 1996
[cited by applicant]
US 5727542A
· King
· 1998
[cited by applicant]
US 5865171A
· Cinquin
· 1999
[cited by applicant]
US 5881715A
· Shibasaki
· 1999
[cited by applicant]
US 5908158A
· Cheiman
· 1999
[cited by applicant]
US 6054486A
· Crow et al.
· 2000
[cited by applicant]
US 6123068A
· Lloyd et al.
· 2000
[cited by applicant]
US 6242482B1
· Shorr et al.
· 2001
[cited by applicant]
US 6357671B1
· Cewers
· 2002
[cited by applicant]
US 6441245B1
· Moriarty et al.
· 2002
[cited by applicant]
US 6521212B1
· Cloutier et al.
· 2003
[cited by applicant]
US 6528688B2
· Moriarty et al.
· 2003
[cited by applicant]
US 6626843B2
· Hillsman
· 2003
[cited by applicant]
US 6700025B2
· Moriarty et al.
· 2004
[cited by applicant]
US 6756033B2
· Cloutier et al.
· 2004
[cited by applicant]
US 6756117B1
· Barnes
· 2004
[cited by applicant]
US 6765117B2
· Moriarty et al.
· 2004
[cited by applicant]
US 6803386B2
· Shorr et al.
· 2004
[cited by applicant]
US 6809223B2
· Moriarty et al.
· 2004
[cited by applicant]
US 7172557B1
· Parker et al.
· 2007
[cited by applicant]
US 7199157B2
· Wade et al.
· 2007
[cited by applicant]
US 7261102B2
· Barney et al.
· 2007
[cited by applicant]
US 7384978B2
· Phares et al.
· 2008
[cited by applicant]
US 7417070B2
· Phares et al.
· 2008
[cited by applicant]
US 7544713B2
· Phares et al.
· 2009
[cited by applicant]
US 7726303B2
· Tyvoll et al.
· 2010
[cited by applicant]
US 7879909B2
· Wade et al.
· 2011
[cited by applicant]
US 7999007B2
· Jeffs et al.
· 2011
[cited by applicant]
US 8232316B2
· Phares et al.
· 2012
[cited by applicant]
US 8242305B2
· Batra et al.
· 2012
[cited by applicant]
US 8252839B2
· Phares et al.
· 2012
[cited by applicant]
US 8349892B2
· Phares
· 2013
[cited by applicant]
US 8350079B2
· Walsh
· 2013
[cited by applicant]
US 8410169B2
· Phares et al.
· 2013
[cited by applicant]
US 8461393B2
· Sharma
· 2013
[cited by applicant]
US 8481782B2
· Batra et al.
· 2013
[cited by applicant]
US 8497393B2
· Batra et al.
· 2013
[cited by applicant]
US 8536363B2
· Phares et al.
· 2013
[cited by applicant]
US 8563614B2
· Wade et al.
· 2013
[cited by applicant]
US 8609728B2
· Rothblatt et al.
· 2013
[cited by applicant]
US 8653137B2
· Jeffs et al.
· 2014
[cited by applicant]
US 8658694B2
· Jeffs et al.
· 2014
[cited by applicant]
US 8747897B2
· Kidane et al.
· 2014
[cited by applicant]
US 8765813B2
· Wade et al.
· 2014
[cited by applicant]
US 8940930B2
· Batra et al.
· 2015
[cited by applicant]
US 9029607B2
· Mcgowan et al.
· 2015
[cited by applicant]
US 9050311B2
· Phares et al.
· 2015
[cited by applicant]
US 9155846B2
· Kern
· 2015
[cited by applicant]
US 9156786B2
· Batra et al.
· 2015
[cited by applicant]
US 9199908B2
· Phares et al.
· 2015
[cited by applicant]
US 9255064B2
· Malinin et al.
· 2016
[cited by applicant]
US 9278901B2
· Phares et al.
· 2016
[cited by applicant]
US 9278902B2
· Tang et al.
· 2016
[cited by applicant]
US 9278903B2
· Tang et al.
· 2016
[cited by applicant]
US 9339507B2
· Olschewski et al.
· 2016
[cited by applicant]
US 9346738B2
· Jain et al.
· 2016
[cited by applicant]
US 9358240B2
· Olschewski et al.
· 2016
[cited by applicant]
US 9371264B2
· Becker et al.
· 2016
[cited by applicant]
US 9388154B2
· Yiannikouros et al.
· 2016
[cited by applicant]
US 9394227B1
· Zhang et al.
· 2016
[cited by applicant]
US 9422223B2
· Phares et al.
· 2016
[cited by applicant]
US 9469600B2
· Malinin et al.
· 2016
[cited by applicant]
US 9505737B2
· Becker et al.
· 2016
[cited by applicant]
US 9624156B2
· Phares et al.
· 2017
[cited by applicant]
US 9643911B2
· Zhang et al.
· 2017
[cited by applicant]
US 9701616B2
· Zhang et al.
· 2017
[cited by applicant]
US 9713599B2
· Wade
· 2017
[cited by applicant]
US 9758465B2
· Laing
· 2017
[cited by applicant]
US 9776982B2
· Becker et al.
· 2017
[cited by applicant]
US 9845305B2
· Becker et al.
· 2017
[cited by applicant]
US 9878972B2
· Phares et al.
· 2018
[cited by applicant]
US 9957200B2
· Beall et al.
· 2018
[cited by applicant]
US 20030192532A1
· Hopkins
· 2003
[cited by applicant]
US 20040063912A1
· Blumberg et al.
· 2004
[cited by applicant]
US 20040149282A1
· Hickle
· 2004
[cited by applicant]
US 20040265238A1
· Chaudry
· 2004
[cited by applicant]
US 20050080140A1
· Hatae et al.
· 2005
[cited by applicant]
US 20060147520A1
· Ruegg
· 2006
[cited by applicant]
US 20080200449A1
· Olschewski et al.
· 2008
[cited by applicant]
US 20080280986A1
· Wade et al.
· 2008
[cited by applicant]
US 20090036465A1
· Roscigno et al.
· 2009
[cited by applicant]
US 20090124697A1
· Cloutier et al.
· 2009
[cited by applicant]
US 20120129941A1
· Wade et al.
· 2012
[cited by applicant]
US 20120177693A1
· Cipolla et al.
· 2012
[cited by applicant]
US 20120197041A1
· Batra et al.
· 2012
[cited by applicant]
US 20130096200A1
· Wade et al.
· 2013
[cited by applicant]
US 20130331593A1
· Mcgowan et al.
· 2013
[cited by applicant]
US 20140018431A1
· Wade et al.
· 2014
[cited by applicant]
US 20140271923A1
· Reid
· 2014
[cited by applicant]
US 20140275616A1
· Batra et al.
· 2014
[cited by applicant]
US 20150126589A1
· Geiger et al.
· 2015
[cited by applicant]
US 20150315114A1
· Hering et al.
· 2015
[cited by applicant]
US 20150328232A1
· Malinin et al.
· 2015
[cited by applicant]
US 20160045470A1
· Reddy et al.
· 2016
[cited by applicant]
US 20170095432A1
· Phares et al.
· 2017
[cited by applicant]
US 20180153847A1
· Phares et al.
· 2018
[cited by applicant]
US 20190290597A1
· Zhang et al.
· 2019
[cited by applicant]
US 20190321290A1
· Guarneri et al.
· 2019
[cited by applicant]
US 20190365778A1
· Olschewski et al.
· 2019
[cited by applicant]
US 20200085741A1
· Kan et al.
· 2020
[cited by applicant]
US 20210177787A1
· Wade
· 2021
[cited by applicant]
US 20210205253A1
· Song et al.
· 2021
[cited by applicant]
US 20220218720A1
· Olschewski et al.
· 2022
[cited by applicant]
US 20220323459A1
· Olschewski et al.
· 2022
[cited by applicant]
US 20230062605A1
· Olschewski et al.
· 2023
[cited by applicant]
AU 1999959533B2
· 2000
[cited by applicant]
CN 109260182A
· 2019
[cited by applicant]
CN 109734580A
· 2019
[cited by applicant]
CN 110585205A
· 2019
[cited by applicant]
DE 19838711C1
· 2000
[cited by applicant]
DE 19934582A1
· 2001
[cited by applicant]
DE 19934582C2
· 2003
[cited by applicant]
FR 2783431A1
· 2000
[cited by applicant]
JP 2003522003A
· 2003
[cited by applicant]
JP 2004512101A
· 2004
[cited by applicant]
JP 2005034341A
· 2005
[cited by applicant]
WO WO9300951A1
· 1993
[cited by applicant]
WO WO0057701A1
· 2000
[cited by applicant]
WO WO0158514A1
· 2001
[cited by applicant]
WO WO0185241A1
· 2001
[cited by applicant]
WO WO0234318A2
· 2002
[cited by applicant]
WO WO2005007081A3
· 2005
[cited by applicant]
WO WO2007134292A2
· 2007
[cited by applicant]
WO WO2008098196A1
· 2008
[cited by applicant]
WO WO2012009097A1
· 2012
[cited by applicant]
WO WO2014085813A1
· 2014
[cited by applicant]
WO WO2015138423A1
· 2015
[cited by applicant]
WO WO2016038532A1
· 2016
[cited by applicant]
WO WO2016055819A1
· 2016
[cited by applicant]
WO WO2016081658A1
· 2016
[cited by applicant]
WO WO2016105538A1
· 2016
[cited by applicant]
WO WO2016176399A1
· 2016
[cited by applicant]
WO WO2016205202A1
· 2016
[cited by applicant]
WO WO2017161387A1
· 2017
[cited by applicant]
WO WO2017192993A1
· 2017
[cited by applicant]
WO WO2018058124A1
· 2018
[cited by applicant]
WO WO2019157337A1
· 2019
[cited by applicant]
WO WO2019237028A1
· 2019
[cited by applicant]
Copeland et al., Management of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD), Frontiers in Medicine, Oct. 13, 2021, 8(743977):1-5.
[cited by applicant]
Lawrence et al., “Converging Pathways: A Review of Pulmonary Hypertension in Interstitial Lung Disease,” Life, Sep. 23, 2024, 14:1203, 1-17.
[cited by applicant]
U.S. Appl. No. 17/486,721, filed Sep. 27, 2021, Olschewski et al.
[cited by applicant]
U.S. Appl. No. 63/036,561, filed Jun. 9, 2020, Batra et al.
[cited by applicant]
U.S. Appl. No. 63/125,145, filed Dec. 14, 2020, Phares et al.
[cited by applicant]
'793 IPR Patent Owner Response, IPR2021-00406, Nov. 10, 2021, 75 pages.
[cited by applicant]
Abe et al., “Effects of inhaled prostacyclin analogue on chronic hypoxic pulmonary hypertension,” J. Cardiovascular Pharmacology, 2001, 37, 239 251.
[cited by applicant]
AccuNeb label, Jun. 2005, 2 pages.
[cited by applicant]
Agarwal et al., “Inhaled Treprostinil in Group-3 Pulmonary Hypertension,” J. Heart Lung Transplant., 2015 34(Suppl S343):959, abstract.
[cited by applicant]
Agnew JE, Bateman RM, Pavia D, Clarke SW. (1984) Radionuclide demonstration of ventilatory abnormalities in mild asthma. Clinical Science; 66: 525-531.
[cited by applicant]
Anderson, Paula J. M.D., “History of Aerosol Therapy: Liquid Nebulization to MDIs to DPIs,” Respiratory Care, Sep. 2005, 50(9):1139-1150.
[cited by applicant]
Annals of the International Commission on Radiological Protection (ICRP) vol. 28, No. 3, 1998, Publication 80, Radiation Dose to Patients from Radiopharmaceuticals.
[cited by applicant]
Aradigm Corporation Form 10-Q for the quarterly period ended Jun. 30, 2009, 37 pages.
[cited by applicant]
Aradigm Corporation news release Oct. 24, 2005, “Aradigm and United Therapeutics Sign Development and Commercialization Agreement Targeting Pulmonary Hypertension,” Red Orbit News, http://www.redorbit.com/modules/news/t…
[cited by applicant]
Aristoff et al., “Synthesis of benzopyran prostaglandins, potent stable prostacyclin analogs, via an intermolecular mitsunobu reaction,” Tetrahedron Letters, 1984, 25(36):3955-3958.
[cited by applicant]
Atkins, Paul J., Ph.D., “Dry Powder Inhalers: An Overview,” Respiratory Care, Oct. 2005, 50(10):1304-1312.
[cited by applicant]
ATS 2020 Virtual Preview: Clinical Trials Session, Jun. 24, 2020, conference.thoracic.org/program/session-information/virtual-clinical-trials.php.
[cited by applicant]
Azmacort label, May 2003, 16 pages.
[cited by applicant]
Badesch et al., “Prostanoid Therapy for Pulmonary Arterial Hypertension,” Journal of the American College of Cardiology, 2004, 43(12:SuppIS):56S-61S.
[cited by applicant]
Bajwa et al., “The safety and tolerability of inhaled treprostinil in patients with pulmonary hypertension and chronic obstructive pulmonary disease,” Pulmonary Circulation, 2017, 7(1):82-88.
[cited by applicant]
Beasley et al., “Preservatives in Nebulizer Solutions: Risks without Benefit,” Pharmacotherapy, 1998, 18(1):130-139.
[cited by applicant]
Bein et al., “Cardiovascular and pulmonary effects of aerosolized prostacyclin administration in severe respiratory failure using a ventilator nebulization system,” J. Cardiovascular Pharmacology, 1996, 27, 583-586.
[cited by applicant]
Bender et al.,. “Nonadherence in asthmatic patients: is there a solution to the problem?”, Ann. Allergy Asthma Immunol., 1997, 79:177-186.
[cited by applicant]
Benedict et al., “Evidence-based pharmacologic management of pulmonary arterial hypertension,” Clinical Therapeutics, 2007, 29, 2134-2153.
[cited by applicant]
Bindl et al., “Aerosolised prostacyclin for pulmonary hypertension in neonates,” Archives of disease in childhood, Fetal and neonatal edition, 1994, 71(3), F214-6.
[cited by applicant]
Blanchard, J.D., Cipolla, D., Liu, K., Morishige, R., Mudumba, S., Thipphawong, J., Taylor, G., Warren, S., Radhakrishnan, R., Van Vlasselaer, R., Visor , G. and Starko, K. (2003) Lung Deposition of Interferon Gamma-1b …
[cited by applicant]
Bonner et al., “Susceptibility of Cyclooxygenase-2-Deficient Mice to Pulmonary Fibrogenesis,” American Journal of Pathology, Aug. 2002, 161(2):459-470.
[cited by applicant]
Booke et al., “Prostaglandins in Patients with Pulmonary Hypertension: The Route of Administration,” Anesth. Analg., 1998, 86:917, Letter to the Editor.
[cited by applicant]
Boyd, B., Noymer, P., Liu, K., Okikawa, J., Hasegawa, D., Warren, S., Taylor, G., Ferguson, E., Schuster, J., Farr, S., and Gonda, I. (2004) Effect of Gender and Device Mouthpiece Shape on Bolus Insulin Aerosol Delivery…
[cited by applicant]
Boyle et al., “So Many Drugs, So Little Time: The Future Challenge of Cystic Fibrosis Care,” Chest, Jan. 2003, 123(1):3-5.
[cited by applicant]
Burger et al., “Inhaled treprostinil vs iloprost: Comparison of adherence, persistence, and health care resource utilization in patients with pulmonary arterial hypertension,” J. Manag. Care Spec. Pharm., 2023, 29(1):10…
[cited by applicant]
Byron, Peter R. “Drug Delivery Devices, Issues in Drug Development,” Proc. Am. Thorac. Soc., 2004, 1:321-328.
[cited by applicant]
Channick et al., “Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension,” J. American College of Cardiology, 2006, 48, 1433-1437.
[cited by applicant]
Chattaraj, Sarat C., “Treprostinil sodium Pharmacia,” Current Opinion in Investigational Drugs, Apr. 2002, 3(4):582-586.
[cited by applicant]
Chew et al., “Pharmaceutical Dry Powder Aerosol Delivery,” Kona, 2001, 19:46-56.
[cited by applicant]
Claim Construction Order, Oct. 21, 2024, in
[cited by applicant]
Clark, A.R., “Medical Aerosol Inhalers: Past, Present, and Future,” Aerosol Science and Technology, Jun. 12, 2007, 22(4):374-391.
[cited by applicant]
Collard et al., “Acute Exacerbation of Idiopathic Pulmonary Fibrosis: An International Working Group Report,” Am. J. Respir. Crit. Care Med., Aug. 1, 2016, 194(3):265-275.
[cited by applicant]
Colthorpe P, Taylor G, Farr SJ. (1997) A comparison of two non-invasive methods for quantifying aerosol deposition in the lungs of rabbits. J. Aerosol Med.; 10:255.
[cited by applicant]
Dalby et al., “A review of the development of Respimat Soft Mist Inhaler,” International Journal of Pharmaceutics, 2004, 283:1-9.
[cited by applicant]
De Wet et al., “Inhaled prostacyclin is safe, effective and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery,” J. Thoracic Cardiovasc. Su…
[cited by applicant]
Decision Granting Institution of Inter Partes Review, IPR2021-00406, U.S. Pat. No. 10,716,793,
[cited by applicant]
Decision in CAFC 2023-1805, Dec. 20, 2023,
[cited by applicant]
Declaration of Douglas Kidder with Exhibits 1 and 2,
[cited by applicant]
Declaration of Dr. Aaron Waxman, Exhibit 2001, May 17, 2021, 21 pages,
[cited by applicant]
Declaration of Dr. Aaron Waxman, M.D., Ph.D, Exhibit 2052, Nov. 10, 2021, 56 pages,
[cited by applicant]
Declaration of Dr. Richard Channick with Appendix A and B,
[cited by applicant]
Declaration of Dr. Werner Seeger, Exhibit 2003, May 10, 2021, 16 pages,
[cited by applicant]
Declaration of Frederic Selck, Ph.D. in Support of Plaintiff's Motion for Preliminary Injunction with Attachments A-1-C-1,
[cited by applicant]
Declaration of Michael J. Flynn in Support of Plaintiff's Motion for Preliminary Injunction with Exhibits 1-7,
[cited by applicant]
Declaration of Michael J. Flynn in Support of Plaintiff's Reply Brief in Support of its Motion for Preliminary Injunction with Exhibits 8-20,
[cited by applicant]
Declaration of Steven Nathan, M.D. in Support of Plaintiff's Motion for Preliminary Injunction with Attachments A-C,
[cited by applicant]
Defendant Liquidia Technologies, Inc.'s Answering Brief in Opposition to Plaintiff's Motion for Preliminary Injunction,
[cited by applicant]
Defendant Liquidia Technologies, Inc.'s Appendix of Exhibits in Support of its Answering Brief in Opposition to Plaintiff's Motion for Preliminary Injunction with Exhibits 1-39,
[cited by applicant]
Defendant Liquidia Technologies, Inc.'s Appendix of Exhibits in Support of its Answering Brief in Opposition to Plaintiff's Motion for Preliminary Injunction, with exhibits 1-39,
[cited by applicant]
Defendant Liquidia Technologies, Inc.'s First Amended Invalidity Contentions,
[cited by applicant]
Defendant Liquidia Technologies, Inc.'s Motion for Leave to Submit a 1-Page Brief Responding to the Court's Questions at the Preliminary Injunction Hearing,
[cited by applicant]
Defendant Liquidia Technologies, Inc.'s Response Regarding bond Figures,
[cited by applicant]
Defendant Watson Laboratories, Inc.'s Invalidity Contentions for U.S. Pat. Nos. 9,339,507 and 9,358,240, in The United States District Court for the District of New Jersey, Civil Action No. 3.15:cv-05723-PGS-LHG, Aug. 5…
[cited by applicant]
Defendant's Answer to First Amended Complaint and Counterclaims, Jan. 8, 2024, in
[cited by applicant]
Denyer et al., “The Adaptive Aerosol Delivery (AAD) Technology: Past, Present, and Future,” Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2010, 23(Supp1):S1-S10.
[cited by applicant]
Dernaika et al., “Iloprost Improves Gas Exchange and Exercise Tolerance in Patients with Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease,” Respiration, 2010, 79:377-382.
[cited by applicant]
District court '793 infringement Trial Opinion,
[cited by applicant]
Dolovich et al., “Device Selection and Outcomes of Aerosol Therapy: Evidence-Based Guidelines,” Chest, Jan. 2005, 127(1):335-371.
[cited by applicant]
Doyle et al., “Inhaled prostacyclin as a selective pulmonary vasodilator,” Anaesthesia and Intensive Care, Aug. 1996, 24(4):514-515.
[cited by applicant]
Dr. Hill's trial court testimony, Mar. 29, 2022, 5 pages, in
[cited by applicant]
Du Bois et al., “Six-Minute-Walk Test in Idiopathic Pulmonary Fibrosis,” Am. J. Respir. Crit. Care Med., 2011, 183:1231-1237.
[cited by applicant]
Dumas et al.,. “Hypoxic pulmonary vasoconstriction,” General Pharmacology, 1999, 33, 289-297.
[cited by applicant]
Dworetz et al., “Survival of infants with persistent pulmonary hypertension without extracorporeal membrane oxygenation,” Pediatrics, 1989, 84, 1-6.
[cited by applicant]
Eli Lilly Press Release, “Eli Lilly and Company Licenses U.S. Rights for Tadalafil PAH Indication to United Therapeutics Corporation,” Nov. 17, 2008, 4 pages.
[cited by applicant]
English translation of OptiNeb User Manual, 2005, 33 pages.
[cited by applicant]
EPA Integrated Risk Information System (IRIS): data sheet for 3-methylphenol (m-cresol). Accessed at http://www.epa.gov/iris/subst/0301/htm on Mar. 9, 2014.
[cited by applicant]
Espacenet European Patent Office machine translation of Buff et al. DE19934582 (A1), Translation provided on Mar. 8, 2013.
[cited by applicant]
Espacenet European Patent Office machine translation of Gessler et al. DE19838711 (C1), Translation provided on Mar. 8, 2013.
[cited by applicant]
EU Community Register, Annexes to Commission Decision C(2005)3436, Sep. 5, 2005, http://ec.europa.eu/health/documents/communityregister/2005/2005090510259/anx_10259_en.pdf (Annex III—Ventavis® Labelling and Package Leaf…
[cited by applicant]
Ewert et al., “Aerosolized iloprost for primary pulmonary hypertension,” New England Journal of Medicine, 2000, 343, 1421-1422.
[cited by applicant]
Ewert et al., “Iloprost als inhalative bzw. Intravenose langzeitbehandlung von patienten mit primarer pulmonaler hypertonie,” Z. Kardiol., 2000, 89, 987-999, English summary on first page.
[cited by applicant]
Exhibit 1002, IPR2021-00406.
[cited by applicant]
Exhibit 1003, IPR2021-00406.
[cited by applicant]
Exhibit 1004, IPR2021-00406.
[cited by applicant]
Exhibit 1005, IPR2021-00406.
[cited by applicant]
Exhibit 1036, IPR2021-00406.
[cited by applicant]
Exhibit 2036, 7 pages,
[cited by applicant]
Exhibit 2084, 9 pages,
[cited by applicant]
Exhibit 2085, 9 pages,
[cited by applicant]
Exhibit 2088, 37 pages,
[cited by applicant]
Exhibit 2089, 260 pages,
[cited by applicant]
Exhibits 1-42 of Defendant's Answer to First Amended Complaint and Counterclaims, Jan. 8, 2024, in
[cited by applicant]
Exhibits 1087-1110 and 1112-1131 to Petitioner's Reply, Feb. 10, 2022, 1,337 pages,
[cited by applicant]
Exhibits 2001-2035 to Patent Owner Preliminary Response, May 17, 2021, 614 pages, IPR2021-00406, U.S. Pat. No. 10,716,793,
[cited by applicant]
Farber et al., “Pulmonary Arterial Hypertension,” The New England Journal of Medicine, 2004, 351:1655-1665.
[cited by applicant]
Faria-Urbina et al., “Inhaled Treprostinil in Pulmonary Hypertension Associated with Lung Disease,” Lung, 2018, 196:139-146.
[cited by applicant]
Farr et al., “Comparison of in vitro and in vivo efficiencies of a novel unit-dose liquid aerosol generator and a pressurized metered dose inhaler,” International Journal of Pharmaceutics, 2000, 198:63-70.
[cited by applicant]
Federal Circuit's Dec. 20, 2023 decision of invalidity for the '793 patent,
[cited by applicant]
Federal Circuit's Mar. 12, 2024 decision denying rehearing re '793 patent,
[cited by applicant]
Federal Circuit's Jul. 24, 2023 decision affirming infringement of the '793 patent.
[cited by applicant]
Findlay et al., “Radioimmunoassay for the Chemical Stable Prostacyclin Analog, 15AU81: a Preliminary Pharmacokinetics Study in the Dog,” Prostaglandins Leukot. Essent. Fatty Acids, Feb. 1993, 48(2):167-174.
[cited by applicant]
Fink et al., “Use of Prostacyclin and its Analogues in the Treatment of Cardiovascular Disease,” Heart Disease, 1999, 1:29-40.
[cited by applicant]
Flolan label, Sep. 2002, 24 pages.
[cited by applicant]
Frijlink et al., “Dry Powder inhalers for pulmonary drug delivery,” Expert Opin. Drug Deliv., 2004, 1(1):67-86.
[cited by applicant]
Geller et al., “ Bolus Inhalation of rhDNase with the AERx System in Subjects with Cystic Fibrosis,” Journal of Aerosol Medicine, 2003, 16(2):175-182.
[cited by applicant]
Geller, David E., M.D., “Comparing Clinical Features of the Nebulizer, Metered-Dose Inhaler, and Dry Powder Inhaler,” Respir. Care, 2005, 50(10):1313-1321.
[cited by applicant]
Gessler et al., “Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension,” Eur. Respir. J., 2001, 17, 14-19.
[cited by applicant]
Ghofrani et al., “New therapies in the treatment of pulmonary hypertension,” HERZ (Heart), Jun. 2005, 30(4):296-302, with English translation.
[cited by applicant]
Ghofrani et al., “Hypoxia- and non-hypoxia-related pulmonary hypertension—Established and new therapies,” Cardiovascular Research, 2006, 72:30-40.
[cited by applicant]
Goldsmith et al., “Inhaled Iloprost In Primary Pulmonary Hypertension,” Drugs, 2004, 64(7):763-773.
[cited by applicant]
Gonda, Igor, “A semi-empirical model of aerosol deposition in the human respiratory tract for mouth inhalation,” J. Pharm. Pharmacol., 1981, 33:692-696.
[cited by applicant]
Gonda, Igor, “Study of the effects of polydispersity of aerosols on regional deposition in the respiratory tract,” J. Pharm. Pharmacol., 1981, 33(Supp):52P.
[cited by applicant]
Hache et al., “Inhaled epoprostenol (prostacyclin) and pulmonary hypertension before cardiac surgery,” The Journal of Thoracic and Cardiovascular Surgery, Mar. 2003, 125:642-649.
[cited by applicant]
Hallioglu et al., “Comparison of Acute Hemodynamic Effects of Aerosolized and Intravenous Iloprost in Secondary Pulmonary Hypertension in Children With Congenital Heart Disease,” Am. J. Cardiol., 2003, 92:1007-1009.
[cited by applicant]
Haraldsson et al., “Comparison of inhaled nitric oxide and inhaled aerosolized prostacyclin in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance,” Chest, 1998, 114, 780-786.
[cited by applicant]
Hill et al., “Inhaled Therapies for Pulmonary Hypertension,” Respiratory Care, Jun. 2015, 60(6):794-805.
[cited by applicant]
Hindle et al., The Drug Delivery Companies Report, Autumn/Winter 2004, 31-34.
[cited by applicant]
Hoeper et al., “Long-term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin Analogue,” The New England Journal of Medicine, Jun. 22, 2000, 342:1866-1870.
[cited by applicant]
Hoeper et al., “A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary hypertension,” J. American College of Cardiology, 2000, 35, 176-182.
[cited by applicant]
Hoeper et al., “Effects of inhaled nitric oxide and aerosolized iloprost in pulmonary veno-occlusive disease,” Respiratory Medicine, 1999, 93, 62-70.
[cited by applicant]
Horn et al., “Treprostinil therapy for pulmonary artery hypertension,” Expert Opinion on Investigational Drugs, 2002, 11(11):1615-1622.
[cited by applicant]
Howarth, P.H., “Why particle size should affect clinical response to inhaled therapy,” Journal of Aerosol Medicine, 2001, 14 Supp. 1, S-27-S-34.
[cited by applicant]
Ichida et al., “Additive effects of beraprost on pulmonary vasodilation by inhaled nitric oxide in children with pulmonary hypertension,” American Journal of Cardiology, 1997, 80, 662-664.
[cited by applicant]
IPR2021-00406 Final Decision Jul. 2022, 49 pages.
[cited by applicant]
Keerthisingham et al., “Cyclooxygenase-2 Deficiency Results in a Loss of the Anti-Proliferative Response to Transforming Growth Factor-Beta in Human Fibrotic Lung Fibroblasts and Promotes Bleomycin-Induced Pulmonary Fib…
[cited by applicant]
King et al., “The Trouble With Group 3 Pulmonary Hypertension in Interstitial Lung Disease,” Chest, 2020, 158(4):1651-1664.
[cited by applicant]
Konorza et al., “Klinisch-pharmakologische Austestung bei pulmonaler Hypertonie zur Therapiefuehrung,” Herz, 2005, 30:286-295, English abstract on first page.
[cited by applicant]
Krause et al., “Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man,” Eur. J. Clin. Pharmacol., 1986, 30, 61-68.
[cited by applicant]
Labiris et al., “Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications,” Br. J. Clin. Pharmacol., 2003, 56(6):600-612.
[cited by applicant]
Laliberte et al., “Pharmacokinetics and Steady-State Bioequivalence of Treprostinil Sodium (Remodulin) Administered by the Intravenous and Subcutaneous Route to Normal Volunteers,” J. Cardiovasc. Pharmacol, Aug. 2004, 4…
[cited by applicant]
Lee et al., “Current strategies for pulmonary arterial hypertension,” J. Internal Medicine, 2005, 258, 199-215.
[cited by applicant]
Letter from Michael J. Flynn to Judge Andrews,
[cited by applicant]
Lettieri et al., “The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis,” Respiratory Medicine, 2006, 100:1734-1741.
[cited by applicant]
Liquidia Notice of Supplemental Authority with Exhibit 1,
[cited by applicant]
Liquidia Notice of Supplemental Authority with Exhibit 1,
[cited by applicant]
Liquidia Technologies Press Release, “Liquidia Announces FDA Acceptance of New Drug Application for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension,” Apr. 8, 2020, 3 pages.
[cited by applicant]
Liquidia Technologies Press Release, “Liquidia Submits New Drug Application for LIQ861 (treprostinil) Inhalation Powder to U.S. Food and Drug Administration for the Treatment of Pulmonary Arterial Hypertension (PAH),” J…
[cited by applicant]
Martin, John C., “Inhaled Form of Remodulin in the Pipeline,” http://www.phneighborhood.com/content/in_the_news/archive_2320,aspx, ph Neighborhood, Oct. 28, 2005, 2 pages.
[cited by applicant]
Max et al., “Inhaled prostacyclin in the treatment of pulmonary hypertension,” Eur. J. Pediatr., 1999, 158 Suppl 1, S23-S26.
[cited by applicant]
McLaughlin et al., “Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension,” Journal of the American College of Cardiology, 2010, 55(18):1915-1922.
[cited by applicant]
McNulty et al., “The Pharmacokinetics and Pharmacodynamics of the Prostacyclin Analog 15AU81 in the Anesthetized Beagle Dog,” Prostaglandins Leukot. Essent. Fatty Acids, Feb. 1993, 48(2):159-166.
[cited by applicant]
Memorandum Opinion, Jun. 18, 2025, in
[cited by applicant]
Memorandum Opinion,
[cited by applicant]
Memorandum Order denying Motion for Preliminary Injunction,
[cited by applicant]
Meyer et al., “Role of pirfenidone in the management of pulmonary fibrosis,” Therapeutics and Clinical Risk Management, 2017, 13:427-437.
[cited by applicant]
Miller et al., “Standardisation of spirometry. Series ATS/ERS Task Force: Standardisation of Lung Function Testing” Eur Respir J 2005; 26: 319-338.
[cited by applicant]
Mueller et al., “Inhaled iloprost in the management of pulmonary hypertension in infants undergoing congenital heart surgery,” European Journal of Anesthesiology, Jun. 2004, 21(Suppl.33):3, Abstract No. 084.
[cited by applicant]
Nathan et al., “Pulmonary Hypertension due to Lung Disease and/or Hypoxia,” Clin. Chest Med., 2013, 34:695-705.
[cited by applicant]
Nathan et al., “Pulmonary hypertension in interstitial lung disease,” Int. J. Clin. Pract., Jul. 2008, 62(Suppl. 160):21-28.
[cited by applicant]
Nathan et al., “Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study,” Lancet Respir. Med., 2019, 7:780-790.
[cited by applicant]
Nathan et al., “Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis,” Respiratory Medicine, 2015, 109:914-9…
[cited by applicant]
National Radiological Protection Board. Doses to Patients from Medical Radiological Examinations in Great Britain. (1986) Radiological Protection Bulletin No. 77.
[cited by applicant]
Nauser et al., “Pulmonary Hypertension: New Perspectives,” CHF, 2003, 9:155-162.
[cited by applicant]
NCT02630316, Safety and Efficacy of Inhaled Treprostinil in Adult PH with ILD Including CPFE, ClinicalTrials.gov, 10 pages, Dec. 19, 2016.
[cited by applicant]
NCT02630316, Safety and Efficacy of Inhaled Treprostinil in Adult PH with ILD Including CPFE, ClinicalTrials.gov, 10 pages, Dec. 7, 2016.
[cited by applicant]
NCT02630316, Safety and Efficacy of Inhaled Treprostinil in Adult PH with ILD Including CPFE, ClinicalTrials.gov, 11 pages, Feb. 1, 2017.
[cited by applicant]
NCT02630316, Safety and Efficacy of Inhaled Treprostinil in Adult PH with ILD Including CPFE, ClinicalTrials.gov, 11 pages, Jan. 12, 2017.
[cited by applicant]
NCT02630316, Safety and Efficacy of Inhaled Treprostinil in Adult PH with ILD Including CPFE, ClinicalTrials.gov, 11 pages, Mar. 1, 2017.
[cited by applicant]
NCT02630316, Safety and Efficacy of Inhaled Treprostinil in Adult PH with ILD Including CPFE, ClinicalTrials.gov, 11 pages, Mar. 17, 2017.
[cited by applicant]
NCT02630316, Safety and Efficacy of Inhaled Treprostinil in Adult PH with ILD Including CPFE, ClinicalTrials.gov, 11 pages, Mar. 9, 2017.
[cited by applicant]
NCT02630316, Safety and Efficacy of Inhaled Treprostinil in Adult PH with ILD Including CPFE, ClinicalTrials.gov, 12 pages, Apr. 13, 2017.
[cited by applicant]
NCT02630316, Safety and Efficacy of Inhaled Treprostinil in Adult PH with ILD Including CPFE, ClinicalTrials.gov, 12 pages, Feb. 9, 2017.
[cited by applicant]
NCT02630316, Safety and Efficacy of Inhaled Treprostinil in Adult PH with ILD Including CPFE, ClinicalTrials.gov, 12 pages, Jul. 13, 2017.
[cited by applicant]
NCT02630316, Safety and Efficacy of Inhaled Treprostinil in Adult PH with ILD Including CPFE, ClinicalTrials.gov, 12 pages, Jul. 19, 2017.
[cited by applicant]
NCT02630316, Safety and Efficacy of Inhaled Treprostinil in Adult PH with ILD Including CPFE, ClinicalTrials.gov, 12 pages, Jul. 31, 2017.
[cited by applicant]
NCT02630316, Safety and Efficacy of Inhaled Treprostinil in Adult PH with ILD Including CPFE, ClinicalTrials.gov, 12 pages, Jul. 5, 2017.
[cited by applicant]
NCT02630316, Safety and Efficacy of Inhaled Treprostinil in Adult PH with ILD Including CPFE, ClinicalTrials.gov, 12 pages, Jun. 19, 2017.
[cited by applicant]
NCT02630316, Safety and Efficacy of Inhaled Treprostinil in Adult PH with ILD Including CPFE, ClinicalTrials.gov, 12 pages, Jun. 2, 2017.
[cited by applicant]
NCT02630316, Safety and Efficacy of Inhaled Treprostinil in Adult PH with ILD Including CPFE, ClinicalTrials.gov, 12 pages, Mar. 27, 2017.
[cited by applicant]
NCT02630316, Safety and Efficacy of Inhaled Treprostinil in Adult PH with ILD Including CPFE, ClinicalTrials.gov, 12 pages, May 19, 2017.
[cited by applicant]
NCT02630316, Safety and Efficacy of Inhaled Treprostinil in Adult PH with ILD Including CPFE, ClinicalTrials.gov, 13 pages, Aug. 16, 2017.
[cited by applicant]
NCT02630316, Safety and Efficacy of Inhaled Treprostinil in Adult PH with ILD Including CPFE, ClinicalTrials.gov, 13 pages, Oct. 13, 2017.
[cited by applicant]
NCT02630316, Safety and Efficacy of Inhaled Treprostinil in Adult PH with ILD Including CPFE, ClinicalTrials.gov, 13 pages, Sep. 1, 2017.
[cited by applicant]
NCT02630316, Safety and Efficacy of Inhaled Treprostinil in Adult PH with ILD Including CPFE, ClinicalTrials.gov, 13 pages, Sep. 12, 2017.
[cited by applicant]
NCT02630316, Safety and Efficacy of Inhaled Treprostinil in Adult PH with ILD Including CPFE, ClinicalTrials.gov, 13 pages, Sep. 14, 2017.
[cited by applicant]
NCT02630316, Safety and Efficacy of Inhaled Treprostinil in Adult PH with ILD Including CPFE, ClinicalTrials.gov, 13 pages, Sep. 20, 2017.
[cited by applicant]
NCT02630316, Safety and Efficacy of Inhaled Treprostinil in Adult PH with ILD Including CPFE, ClinicalTrials.gov, 13 pages, Sep. 8, 2017.
[cited by applicant]
NCT02630316, Safety and Efficacy of Inhaled Treprostinil in Adult PH with ILD Including CPFE, ClinicalTrials.gov, 14 pages, Nov. 14, 2017.
[cited by applicant]
NCT02630316, Safety and Efficacy of Inhaled Treprostinil in Adult PH with ILD Including CPFE, ClinicalTrials.gov, 14 pages, Oct. 25, 2017.
[cited by applicant]
NCT02630316, Safety and Efficacy of Inhaled Treprostinil in Adult PH with ILD Including CPFE, ClinicalTrials.gov, 15 pages, Dec. 20, 2019.
[cited by applicant]
NCT02630316, Safety and Efficacy of Inhaled Treprostinil in Adult PH with ILD Including CPFE, ClinicalTrials.gov, 15 pages, Mar. 6, 2018.
[cited by applicant]
NCT02630316, Safety and Efficacy of Inhaled Treprostinil in Adult PH with ILD Including CPFE, ClinicalTrials.gov, 15 pages, Oct. 10, 2019.
[cited by applicant]
NCT02630316, Safety and Efficacy of Inhaled Treprostinil in Adult PH with ILD Including CPFE, ClinicalTrials.gov, 15 pages, Oct. 23, 2019.
[cited by applicant]
NCT02630316, Safety and Efficacy of Inhaled Treprostinil in Adult PH with ILD Including CPFE, ClinicalTrials.gov, 15 pages, Oct. 28, 2019.
[cited by applicant]
NCT02630316, Safety and Efficacy of Inhaled Treprostinil in Adult PH with ILD Including CPFE, ClinicalTrials.gov, 15 pages, Oct. 8, 2019.
[cited by applicant]
NCT02630316, Safety and Efficacy of Inhaled Treprostinil in Adult PH with ILD Including CPFE, ClinicalTrials.gov, 16 pages, Apr. 15, 2019.
[cited by applicant]
NCT02630316, Safety and Efficacy of Inhaled Treprostinil in Adult PH with ILD Including CPFE, ClinicalTrials.gov, 16 pages, Apr. 19, 2019.
[cited by applicant]